Difference between revisions of "Ultrasonography of cirrhosis"
Jump to navigation
Jump to search
(Started) |
(+Planning) |
||
| Line 5: | Line 5: | ||
==Planning== | ==Planning== | ||
| − | ;Choice of investigation: US is also typically the initial, first-line modality choice for the diagnosis and follow-up of portal hypertension.<ref name="BandaliMirakhur2017">{{cite journal|last1=Bandali|first1=Murad Feroz|last2=Mirakhur|first2=Anirudh|last3=Lee|first3=Edward Wolfgang|last4=Ferris|first4=Mollie Clarke|last5=Sadler|first5=David James|last6=Gray|first6=Robin Ritchie|last7=Wong|first7=Jason Kam|title=Portal hypertension: Imaging of portosystemic collateral pathways and associated image-guided therapy|journal=World Journal of Gastroenterology|volume=23|issue=10|year=2017|pages=1735|issn=1007-9327|doi=10.3748/wjg.v23.i10.1735}}</ref> | + | ;Choice of investigation |
| + | The diagnosis of cirrhosis can be made by physical examination and blood testing alone,<ref>{{cite journal|last=Udell|first=JA |author2=Wang, CS |author3=Tinmouth, J |author4=FitzGerald, JM |author5=Ayas, NT |author6=Simel, DL |author7=Schulzer, M |author8=Mak, E |author9=Yoshida, EM|title=Does this patient with liver disease have cirrhosis?|journal=JAMA: The Journal of the American Medical Association|date=Feb 22, 2012|volume=307|issue=8|pages=832–42|pmid=22357834|doi=10.1001/jama.2012.186}}</ref> but ultrasonography is very helpful as an additional diagnostic tool, such as in subtle disease. Ultrasonography is the first-line modality of medical imaging in patients with suspected cirrhosis and/or portal hypertension.<ref name="ProcopetBerzigotti2017">{{cite journal|last1=Procopet|first1=Bogdan|last2=Berzigotti|first2=Annalisa|title=Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy|journal=Gastroenterology Report|volume=5|issue=2|year=2017|pages=79–89|issn=2052-0034|doi=10.1093/gastro/gox012}}</ref> US is also typically the initial, first-line modality choice for the diagnosis and follow-up of portal hypertension.<ref name="BandaliMirakhur2017">{{cite journal|last1=Bandali|first1=Murad Feroz|last2=Mirakhur|first2=Anirudh|last3=Lee|first3=Edward Wolfgang|last4=Ferris|first4=Mollie Clarke|last5=Sadler|first5=David James|last6=Gray|first6=Robin Ritchie|last7=Wong|first7=Jason Kam|title=Portal hypertension: Imaging of portosystemic collateral pathways and associated image-guided therapy|journal=World Journal of Gastroenterology|volume=23|issue=10|year=2017|pages=1735|issn=1007-9327|doi=10.3748/wjg.v23.i10.1735}}</ref> | ||
==Diagnosis== | ==Diagnosis== | ||
| Line 29: | Line 30: | ||
:*[[Splenomegaly]]<ref name=Radiopaedia-Cirrhosis/> | :*[[Splenomegaly]]<ref name=Radiopaedia-Cirrhosis/> | ||
:*Ascites<ref name=Radiopaedia-Cirrhosis/> | :*Ascites<ref name=Radiopaedia-Cirrhosis/> | ||
| + | |||
| + | ==Surveillance== | ||
| + | In patients with a diagnosis, surveillance [[ultrasonography of hepatocellular cancer]] (HCC) is indicated, generally every 6 months.<ref name="FateenRyder2017">{{cite journal|last1=Fateen|first1=Waleed|last2=Ryder|first2=Stephen|title=Screening for hepatocellular carcinoma: patient selection and perspectives|journal=Journal of Hepatocellular Carcinoma|volume=Volume 4|year=2017|pages=71–79|issn=2253-5969|doi=10.2147/JHC.S105777}}</ref> | ||
| + | |||
==References== | ==References== | ||
{{reflist}} | {{reflist}} | ||
Revision as of 16:16, 16 June 2018
Author:
Mikael Häggström [notes 1]
Contents
Planning
- Choice of investigation
The diagnosis of cirrhosis can be made by physical examination and blood testing alone,[1] but ultrasonography is very helpful as an additional diagnostic tool, such as in subtle disease. Ultrasonography is the first-line modality of medical imaging in patients with suspected cirrhosis and/or portal hypertension.[2] US is also typically the initial, first-line modality choice for the diagnosis and follow-up of portal hypertension.[3]
Diagnosis
Cirrhosis is indicated by:
- Surface nodularity: (sensitivity 88%, specificity 82-95%)[4]
- General coarse and heterogeneous texture[4]
- Segmental hypertrophy or atrophy[4]
- Dilated portal vein: >13 mm (sensitivity 42%, specificity 95-100%)[4]
- Slow portal venous flow on Doppler: <15 cm/sec[4]
- Reversal or alternating directions of portal venous flow[4]
- Portal venous thrombosis with or without cavernous transformation[4]
- Dilated superior mesenteric vein and splenic vein of > 10mm.[4] These should be measured during deep inspiration since it may vary with respiration.[4]
- Loss of respiratory variation in superior mesenteric vein and splenic vein on spectral Doppler[4]
- Re-canalisation and hepatofugal paraumbilical venous flow.[4]
- Dilated porto-systemic collaterals.[4]
- Portalisation of hepatic vein flow on Doppler[4]
- Corkscrew appearance of hepatic arteries[4]
- Increased velocity in hepatic artery[4]
- Splenomegaly[4]
- Ascites[4]
Surveillance
In patients with a diagnosis, surveillance ultrasonography of hepatocellular cancer (HCC) is indicated, generally every 6 months.[5]
References
- ↑ Udell, JA; Wang, CS; Tinmouth, J; FitzGerald, JM; Ayas, NT; Simel, DL; Schulzer, M; Mak, E; et al. (Feb 22, 2012). "Does this patient with liver disease have cirrhosis? ". JAMA: The Journal of the American Medical Association 307 (8): 832–42. doi:. PMID 22357834.
- ↑ Procopet, Bogdan; Berzigotti, Annalisa (2017). "Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy ". Gastroenterology Report 5 (2): 79–89. doi:. ISSN 2052-0034.
- ↑ Bandali, Murad Feroz; Mirakhur, Anirudh; Lee, Edward Wolfgang; Ferris, Mollie Clarke; Sadler, David James; Gray, Robin Ritchie; Wong, Jason Kam (2017). "Portal hypertension: Imaging of portosystemic collateral pathways and associated image-guided therapy ". World Journal of Gastroenterology 23 (10): 1735. doi:. ISSN 1007-9327.
- ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 4.13 4.14 4.15 4.16 4.17 4.18 4.19 4.20 Dr Yuranga Weerakkody, A.Prof Frank Gaillard et al.. Cirrhosis. Radiopaedia. Retrieved on 2018-06-16.
- ↑ Fateen, Waleed; Ryder, Stephen (2017). "Screening for hepatocellular carcinoma: patient selection and perspectives ". Journal of Hepatocellular Carcinoma Volume 4: 71–79. doi:. ISSN 2253-5969.
Cite error: <ref> tags exist for a group named "notes", but no corresponding <references group="notes"/> tag was found, or a closing </ref> is missing
